METHODICAL REPORT ON DISCLOSURE OF THE VALUES TRANSFERRED BY UAB "MYLAN HEALTHCARE"/SIA "MEDA PHARMA"

In reference to Paragraph 3.05 of the Disclosure Code of HCP/HCO Information adopted by the Association of Drug Manufacturers (ADM) during the General Meeting of the Members on 16 January 2014, by this Report Company UAB "Mylan Healthcare"/SIA "Meda Pharma" summarises the methods used for preparation of information to be disclosed and identification of the transferred values.

<u>Transferred values</u>: values transferred directly and indirectly in cash, in kind or otherwise for the purpose of promotion of drugs for human use or other purposes. <u>Values transferred directly</u> are defined as those directly provided by UAB "Mylan Healthcare"/SIA "Meda Pharma" to HCPs/HCOs [Health Care Professionals / Health Care Organizations]. <u>Values transferred indirectly</u> are defined as the values transferred to HCPs/HCOs by an agent, when UAB "Mylan Healthcare"/SIA "Meda Pharma" is able to identify a specific HCP/HCO having received the transferred values.

The Report covers the values transferred to HCPs/HCOs with principal place of business / headquarters located in Lithuania.

<u>HCO</u>: a public or a private establishment, a company, or an organization or a structural unit thereof holding a personal health care licence; HCPs are the end recipients of the transferred values at medical faculties of universities; an association uniting HCPs.

<u>HCP</u>: persons holding a valid licence for medical practice, pharmacist practice, and/ or general nursing practice; persons on the list of assistant pharmacists; nursing assistants.

<u>Event</u>: construed in reference to the definition given in Art. 10 of the Code of Ethics for Pharmaceutical Marketing adopted by the ADM during the General Meeting of the Members on 16 January 2014.

<u>Personal data protection</u>: the legislations require obtaining an HCP's consent before making the values transferred to the HCP public. UAB "Mylan Healthcare"/SIA "Meda Pharma" seeks obtaining consent of every HCP, whom the value was transferred to. Upon the HCP refusal to give consent or upon withdrawal of the given consent prior to making the transferred values public, all values transferred to such an HCP are disclosed as depersonalized data (i.e., they are included in the total sum of the values transferred to such recipients in a respective column in the report). If an HCP withdraws one's consent for making his/ her data public after the values transferred to him/ her have already been made public, the data of such an HCP would be depersonalized and made public as depersonalized data (i.e., they would be disclosed by including them in the total sum of the values transferred to such recipients in a respective column in the Report). Your data collected by UAB "Mylan Healthcare"/SIA "Meda Pharma" prior to withdrawal of your consent, but not made public yet would be made public as depersonalized data in future until you give your consent for making the transferred values public again.

When an HCP, who objected making the transferred value public, gave consent for making the value transferred to him/ her public at a later time, UAB "Mylan Healthcare"/SIA "Meda Pharma" would make the values transferred to such an HCP after giving this consent public on an individual level. Values transferred to such an HCP prior to obtaining his/ her consent would be included in the cumulative sum in the Report based on a respective category.

UAB "Mylan Healthcare"/SIA "Meda Pharma" discloses the transferred values on the site at www.mylan.lt. A link to the data published on this site is available on the website at www.vaistukodeksas.lt. The value is available to the public on the sites for 3 years since publishing thereof for the first time. UAB "Mylan Healthcare"/SIA "Meda Pharma" processes HCPs' personal data on the transferred values during the reporting period and 5 years after the end of the reporting period.

<u>Value transfer date</u>: whereas the value transfer date typically differs from the date of the event in respect of which the value is transferred, UAB "Mylan Healthcare"/SIA "Meda Pharma" clarifies assignment of the transferred values to the reporting period of each year. The values transferred to an HCP (by sponsoring his/ her participation in an international congress) are included in the reporting period of each year considering the actual invoice payment date. If the HCP fails to attend the congress, it is deemed that the value was not transferred to the HCP, thus it is not disclosed in the Report.

The values directly transferred on the basis of a copyright agreement, service agreement, sponsorship agreement or other type of agreement with HCPs/HCOs are included in the reporting period of each year based on the date when the payment was made to the HCPs/HCOs by UAB "Mylan Healthcare" (not based on the invoice issue date or the agreement signing date).

These principles of disclosure of transferred values would be consistently applicable during the next reporting periods.

<u>Currency</u>: the Company transferred the values and publishes them in Euro.

<u>VAT</u>: the transferred values are disclosed by including VAT applicable in the Republic of Lithuania.

<u>Unique state identifier</u>: in respect of an HCP it refers to a stamp and/ or licence number; in respect of an HCO it refers to a legal entity code.

<u>Support for HCOs</u>: values directly transferred on the basis of support agreements for the objectives of the HCOs' operations or for a specific target purpose (e.g., an occupational event organized by the HCO; for the HCOs' members' participation in an international scientific congress) are disclosed. As the HCO decides on which HCPs would attend a congress independently and UAB "Mylan Healthcare"/SIA "Meda Pharma" does not know this, the transferred value is disclosed as support for the HCO.

If the provided support has not been used by am HCO before disclosure of the values and UAB "Mylan Healthcare"/SIA "Meda Pharma" did not receive a report on use of the support, the transferred value (a part of it) in respect of which a report has not been received is disclosed as support for the HCO.

<u>Contribution to costs of an HCO's event</u>: values related to occupational events directly and indirectly transferred to an HCO by UAB "Mylan Healthcare"/SIA "Meda Pharma" are disclosed by specifying the amounts in a respective column in the Report.

<u>Contribution to covering an HCP's costs related to events</u>: values transferred in support of an HCP's participation in international scientific congresses are disclosed on an individual level based on a respective Report category.

Expense category "Travel and accommodation costs" includes airplane ticket costs, transportation costs in the state of the event, accommodation costs, travel agency's fee for organization of the trip.

<u>Compensation for services or consultations provided by an HCP:</u> values transferred to HCPs on the basis of contracts (e.g., for preparation of copyright research articles, preparation and/ or presentation of research reports) are disclosed.

UAB "Mylan Healthcare"/SIA "Meda Pharma" included all related costs in the price of HCPs' services and did not make any additional payments to them during the reporting period.

The amount of the value transferred to an HCP, who is not engaged in individual activities, for the services provided to UAB "Mylan Healthcare"/SIA "Meda Pharma" indicated in this column of the Report includes personal income tax and all contributions due to Sodra [State Social Insurance Fund Board].